Engineered DLL4 Ligands for Broad Notch Receptor Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low binding affinity between Delta-like (DLL) or Jagged (Jag) ligands and Notch receptors limits their utility in biomedical applications, particularly in cancer therapeutics.
Innovation Solution
Engineered DLL4 proteins with conservative amino acid substitutions at specific residues, enhancing their affinity for multiple human Notch receptors through structure-guided directed evolution and selection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Force
If conservative amino acid substitutions are introduced at specific residues (28, 107, 143, 194, 206, 256, 257, 271, 280, 301, 305) in DLL4 proteins, then binding affinity for Notch receptors is significantly increased, but protein structure complexity increases
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (28, 107, 143, 194, 206, 256, 257, 271, 280, 301, 305) in the DLL4 protein sequence. These conservative substitutions alter local chemical properties and bonding characteristics, thereby enhancing binding affinity to Notch receptors while maintaining overall protein fold integrity.
Solution Approach 2:
The engineered DLL4 proteins represent composite molecular structures combining wild-type and mutated amino acid sequences. The chimeric nature of these proteins, integrating beneficial mutations from different sources, creates a composite structure that achieves superior binding affinity compared to either wild-type or single-mutation variants.
2Reliability
If multiple conservative amino acid substitutions are made in DLL4 proteins to enhance binding affinity, then therapeutic efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent systematically modifies multiple parameters of the DLL4 protein simultaneously (amino acid identity at 11 specific positions), creating a multi-parameter optimized therapeutic agent. This comprehensive parameter optimization ensures high binding affinity and therapeutic efficacy while the mutations are designed to be conservative to maintain protein stability during manufacturing.
Solution Approach 2:
The binding interface of the engineered DLL4 proteins is pre-optimized through directed evolution and structure-guided design before therapeutic application. By预先 (in advance) engineering the high-affinity binding interface, the protein requires less post-manufacturing adjustment and quality control intervention, thereby improving ease of manufacture despite the multiple substitutions.
3Force
If structure-guided directed evolution is used to engineer DLL4 ligands, then binding affinity for multiple Notch receptors is enhanced, but development time increases
Solution Approach 1:
The patent employs structure-guided directed evolution, which uses pre-acquired structural information of Notch-DLL4 complexes to guide the engineering process. By preliminarily analyzing the binding interface structure and identifying key residues before experimentation, the development process is accelerated while achieving high binding affinity across multiple Notch receptor subtypes.
Solution Approach 2:
The engineered DLL4 proteins achieve multi-functionality by binding to multiple Notch receptor subtypes (Notch1, Notch2, Notch3, Notch4) with high affinity. This universal binding capability is achieved through conservative amino acid substitutions that preserve the core binding mechanism while enhancing interaction with different receptor variants, reducing the need for separate development programs for each receptor subtype.
Data Source
AI summary
Disclosed are compositions and methods for engineered DLL4 proteins. In one aspect, disclosed herein are engineered DLL4 proteins comprising a conservative amino acid substitution at a residue corresponding to residues 28, 107, 143, 194, and 206 as set forth in SEQ ID NO: 1 and further comprising at least one conservative amino acid substitution at residues 256, 257, 271, 280, 301, and 305 as set forth in SEQ ID NO: 1.